消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌的临床研究

目的探讨消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌的临床疗效。方法选取2014年1月—2015年9月在蕲春县人民医院接受治疗的中晚期原发性肝癌患者82例,按照治疗方法的差别分成对照组和治疗组,每组各41例,对照组患者静脉滴注榄香烯注射液,0.6 g加入5%葡萄糖溶液500 m L,1次/d。治疗组在对照组基础上静脉滴注消癌平注射液,40 m L加入5%葡萄糖溶液250 m L,1次/d。两组患者均连续治疗2个疗程,其中3周为1个疗程,休息1周后进行下1个疗程治疗。观察两组近期临床疗效和生存质量改善率,比较两组CD~(3+)、CD~(4+)和CD~(4+)/CD~(8+)淋巴细胞水平变化,并对比两组治疗前后血清MMP-2和MMP-9水平的变化。结果治疗后,对照组客观缓解率(ORR)43.90%,临床获益率(CBR)75.61%,治疗组客观缓解率(ORR)65.85%,临床获益率(CBR)92.68%,两组ORR、CBR比较差异有统计学意义(P0.05);对照组与治疗组生存质量改善率分别为80.49%、95.12%,两组比较差异具有统计学意义(P0.05);两组患者CD~(3+)、CD~(4+)、CD~(4+)/CD~(8+)均较治疗前明显增高,同组治疗前后差异具有统计学意义(P0.05),但治疗组增高更明显,与对照组相比差异具有统计学意义(P0.05);两组血清MMP-2和MMP-9水平均比同组治疗前明显降低,差异具有统计学意义(P0.05),治疗组降低的更显著,与对照组相比差异具有统计学意义(P0.05)。结论消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌具有良好的临床疗效,安全性高,具有一定的临床推广应用价值。

Clinical study on Xiaoaiping Injection combined with Elemene Injection in treatment of advanced primary hepatocellular carcinoma

ObjectiveTo investigate the clinical effect and safety of Xiaoaiping Injection combined with Elemene Injection in treatment of advanced primary hepatocellular carcinoma. Methods Patients (82 cases) with advanced primary hepatocellular carcinoma in Qichun People''s Hospital from January 2014 to September 2015 were divided into control and treatment groups, each group had 41 cases. Patients in the control group were iv administered with Elemene Injection, 0.6 g Elemene Injection added into 5% glucose solution 500 mL, once daily. The patients in treatment group were iv administered with Xiaoaiping Injection on the basis of control group, 40 mL Xiaoaiping Injection added into 5% glucose solution 250 mL, once daily. The patients in two groups were treated for two courses of treatment, a course of 3 weeks, the next course was progressed after one week of rest. After treatment, the clinical efficacies and the life quality were evaluated, and the changes of CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, MMP-2, and MMP-9 in two groups were compared before and after treatment. Results After treatment, ORR and CBR in the control group respectively were 43.90% and 75.61%, accordingly 65.85% and 92.68% in the treatment group, and there were differences between two groups (P < 0.05); Improvement rate of survival quality in the control and treatment groups were 80.49% and 95.12%, respectively, and there were differences between two groups (P < 0.05); After treatment, CD³⁺, CD⁴⁺ and CD⁴⁺/CD⁸⁺ were higher than those before treatment, and the difference was statistically significant in the same group (P < 0.05). Compared with the control group, the observational indexes were much better in the treatment group, with significant difference between two groups (P < 0.05); The serum MMP-2 and MMP-9 levels were lower than those before treatment, and the difference was statistically significant in the same group (P < 0.05), but the indexes in treatment group were significantly lower than that in control group, with significant difference between two groups (P < 0.05). Conclusion Xiaoaiping Injection combined with Elemene Injection has good clinical efficacy in the treatment of advanced primary hepatocellular carcinoma, and has high safety, which has a certain clinical application value.